Diyabetik Makula Ödeminde İntravitreal Bevacizumab Tedavisinin Santral Makula Kalınlığı Ve Santral Retina Duyarlılığı Üzerine Etkisi

Amaç: Diyabetik makula ödeminde (DMÖ) intravitreal bevacizumab (İVB) tedavisinin görme keskinliği (GK), santral makula kalınlığı (SMK) ve santral retina duyarlılığı (SRD) üzerine etkisini değerlendirmek. Gereç ve Yöntem: DMÖ olan 12 hastanın 16 gözüne IVB tedavisi uygulandı. Hastaların GK, SMK, SRD ölçümleri tedaviden önce, birinci hafta, birinci ay ve üçüncü ayda yapıldı. Bulgular: Yaş ortalaması 60,8±5,7 idi. Görme keskinliği ortalaması başlangıçta ve enjeksiyondan 1 hafta, 1 ay, 3 ay sonra sırasıyla 0,12±0,07, 0,15±0,09, 0,22±0,14 ve 0,21±0,13 olarak bulundu. Başlangıca göre enjeksiyondan 1 hafta, 1 ay ve 3 ay sonra görme keskinliğindeki artış istatistiksel olarak anlamlı idi (p

Anahtar Kelimeler:

Bevacizumab, diyabetik retinopati

PDF

___

1. Kim JW, Ai E. Diabetic retinopathy. In: Regillo CD, Brown GC, Flynn Jr HW, eds. Vitreoretinal disease, The Essentials, New York;Thime;1999:133-59.
2. Klein R, Klein BE, Moss SE. Visual impairment in diabetes. Ophthalmology 1984; 91:1-9.
3. Diabetes Control and Complication Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of longterm complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329:977-86.
4. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. UKPDS 33. Lancet 1998; 352:837-53.
5. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study Research Group. Arch Ophthalmol 1985; 103:1796-806.
6. Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS Report Number 8. Diabetic Retinopathy Study Research Group. Ophthalmology. 1981; 88:583-600.
7. Pendergast SD, Hassan TS, Williams GA, Margherio RR, Ferrone PJ, Garretson BR, et al. Vitrectomy for diffuse diabetic macular edema associated with a taut premacular posterior hyaloid. Am J Ophthalmol 2000; 130:178-86.
8. Haritoglou C, Kook D, Neubauer A, Wolf A, Priglinger S, Strauss R, et al. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. Retina 2006; 26:999-1005.
9. Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology. 2006; 113:363-72.
10. Spaide RF, Fisher YL. Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina. 2006; 26:275-8.
11. Mason JO 3rd, Albert MA Jr, Vail R. Intravitreal bevacizumab (Avastin) for refractory pseudophakic cystoid macular edema. Retina. 2006; 26:356-7.
12. Park J, Lee M. Short-term effects and safety on acute increase of intraocular pressure after intravitreal bevacizumab injection on corneal endothelial cells. BMC Opthalmol. 2018;18:17.
13.Zarbin MA. Anti-VEGF Agents and the Risk of Arteriothrombotic Events. Asia Pac J Opthalmol (Phila). 2018;7:63-67.
14. Yılmaz G. Kuçukerdonmez CF. Anjiogenesis and VEGF. Ed: Karacorlu M, Karacorlu SA, Ozdemir H. Eye Disease and anti-VEGF Treatment. Istanbul 2010:11-21.
15. Hasanreisoglu B, Ozdek S. Diabetic Retinopathy and Anti-VEGF Treatment. Karacorlu M, Karacorlu SA, Ozdemir H. Eye Disease and anti-VEGF Treatment. Istanbul 2010:133-44.
16. Arevalo JF, Sanchez JG, Wu L, Maia M, Alezzandrini AA, Brito M, et al. Primary intravitreal bevacizumab for diffuse diabetic macular edema: the Pan-American Collaborative Retina Study Group at 24 months. Ophthalmology. 2009; 116(8):1488-97.
17. Kook D, Wolf A, Kreutzer T, et al. Long-term effect of intravitreal bevacizumab (avastin) in patients with chronic diffuse diabetic macular edema. Retina. 2008; 28(8):1053-60.
18. Kumar A, Sinha S. Intravitreal bevacizumab (Avastin) treat¬ment of diffuse diabetic macular edema in an Indian popula¬tion. Indian J Ophtalmol 2007;55:451-5.
19. Lam DS, Lai TY, Lee VY, Chan CK, Liu DT, Mohamed S, et al. Efficacy of 1.25 mg versus 2.5 mg intravitreal bevacizumab for diabetic macular edema: six months results of a randomized controlled trial. Retina 2009;29:292-9.
20. Soheilian M, Ramezani A, Yaseri M, Mirdehghan SA, Obudi A, Bijanzadeh B. Initial macular thickness and response to treatment in diabetic macular edema. Retina. 2011;31:1564-73.
21. Diabetic Retinopathy Clinical Research Network, Wells JA, Glassman AR, Ayala AR, et all: Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med. 2015; 372: 1193–203
22. Arevalo JF, Lasave AF, Wu L, et all; Pan-American Collaborative Retina Study Group (PACORES): Intravitreal bevacizumab for diabetic macular oedema: 5-year results of the Pan-American Collaborative Retina Study group. Br J Ophthalmol. 2016; 100: 1605– 10.
23. Arevalo JF, Liu TYA; Pan-American Collaborative Retina Study Group (PACORES). Intravitreal Bevacizumab in Diabetic Retinopathy. Recommendations from the Pan-American Collaborative Retina Study Group (PACORES): The 2016 Knobloch Lecture. Asia Pac J Ophthalmol (Phila). 2018; 7: 36-9.
24. Jafri AS, Rehman A, Mirani AH, Memon S. Outcomes of intravitreal bevacizumab and macular photocoagulation for treatment of diabetic macular edema in a tertiary care eye hospital, Karachi. Pak J Med Sci. 2017;33:1215-9.
25. Kriechbaum K, Prager S, Mylonas G, Scholda C, Rainer G, Funk M, et al.; Diabetic Retinopathy Research Group. Intravitreal bevacizumab (Avastin)versus triamcinolone (Volon A) for treatment of diabetic macular edema: one-year results. Eye (Lond). 2014;28:9-16.